PerkinElmer Drops Legal Actions Against MDS, Life Tech; FTC Gives Nod to Analytical Technologies Sale | GenomeWeb

This story originally ran on Jan. 27 and was updated to include information about the FTC's approval of the MDS Analytical Technologies sale to Danaher.

Legal action by PerkinElmer that had threatened to hold up Danaher's purchase of Applied Biosystems' and MDS' mass spectrometry joint venture were cleared this week, paving the way for Danaher to proceed with the $1.1 billion deal.

Separately, the US Federal Trade Commission provisionally approved the sale of MDS' Analytical Technologies division to Danaher this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.